ORKA Oruka Therapeutics Inc.

$ORKA unfortunately what it looks like is that the market is waiting for that 52 week data in December which I continue to remain positive on and that would prove that this could potentially be a once a year dosed product. Today’s read out confirmed six month, durability only.

$ORKA see everybody in December when the 52 week phase II readout occurs. I doubt there will be any meaningful upward movement until we get closerto that time point.